FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2161577092> ?p ?o ?g. }

• W2161577092 endingPage "388" @default.
• W2161577092 startingPage "381" @default.
• W2161577092 abstract "To review the epidemiology, pathophysiology, clinical features, diagnosis, and treatment of Gaucher's disease, focusing on the role of enzyme replacement therapy.A MEDLINE search (from 1984 to July 1995) of English-language literature pertaining to the treatment of Gaucher's disease was performed. Additional references were obtained by reviewing the references of pertinent articles identified through the search. Tertiary sources were also used.Articles with information on enzyme treatment were selected for review. Articles containing other interesting aspects of the disease or its treatment were also included.Gaucher's disease is the most common lipid storage disorder known and results from a genetic deficiency of the enzyme glucocerebrosidase (glucosylceramidase). Enzyme deficiency results in accumulation of glucocerebroside within the reticuloendothelial system. It may present with hepatosplenomegaly, bone marrow suppression, and bone lesions. The most common of the three subtypes, type 1, is non-neuronopathic. In the rare neuronopathic subtypes, type 2 or 3, there may also be nerve cell destruction within the central nervous system with acute brainstem dysfunction or progressive neurologic deterioration, respectively. In 1991, enzyme treatment became available with the marketing of alglucerase, a placentally derived modified form of glucocerebrosidase. In 1994, a recombinant DNA modified form of glucocerebrosidase, known as imiglucerase, was developed to replace alglucerase. Most published data on enzyme therapy are with alglucerase in patients with type 1 disease. A dosage regimen of 60 units/kg every 2 weeks for moderately to severely ill patients has been effective in reducing hepatosplenomegaly, improving anemia and thrombocytopenia, as well as improving weight gain and growth in children and increasing vigor and self-esteem in adults. Bone involvement is often slow to respond to therapy although pain is frequently improved. Controversy exists as to whether lower dosage regimens are as effective. The role of enzyme therapy in the rarer neuronopathic subtypes remains to be determined, but initial reports have been disappointing.Enzyme replacement therapy is available for the treatment of type 1 Gaucher's disease, resulting in clinical improvement with enhanced quality of life within the first year of treatment, although improvement in bone disease can take longer. Doses of 60 units/kg every 2 weeks are of clinical benefit to patients with moderate to severe disease. A number of lower dosage regimens have been evaluated in small groups of patients, with satisfactory clinical responses occurring in some of these patients." @default.
• W2161577092 created "2016-06-24" @default.
• W2161577092 creator A5091060989 @default.
• W2161577092 date "1996-04-01" @default.
• W2161577092 modified "2023-09-26" @default.
• W2161577092 title "Gaucher's Disease: A Review" @default.
• W2161577092 cites W1593780294 @default.
• W2161577092 cites W1974211186 @default.
• W2161577092 cites W1974747412 @default.
• W2161577092 cites W1979730698 @default.
• W2161577092 cites W1998164429 @default.
• W2161577092 cites W1998222693 @default.
• W2161577092 cites W2002001461 @default.
• W2161577092 cites W2005428069 @default.
• W2161577092 cites W2014303554 @default.
• W2161577092 cites W2018393512 @default.
• W2161577092 cites W2018603101 @default.
• W2161577092 cites W2022706586 @default.
• W2161577092 cites W2061700574 @default.
• W2161577092 cites W2064430381 @default.
• W2161577092 cites W2070801058 @default.
• W2161577092 cites W2076780197 @default.
• W2161577092 cites W2077868231 @default.
• W2161577092 cites W2118170260 @default.
• W2161577092 cites W2257876259 @default.
• W2161577092 cites W230215977 @default.
• W2161577092 cites W2322128806 @default.
• W2161577092 cites W2326229951 @default.
• W2161577092 cites W2371946969 @default.
• W2161577092 cites W2418686180 @default.
• W2161577092 cites W298365889 @default.
• W2161577092 cites W3026424698 @default.
• W2161577092 cites W4302554796 @default.
• W2161577092 doi "https://doi.org/10.1177/106002809603000411" @default.
• W2161577092 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/8729893" @default.
• W2161577092 hasPublicationYear "1996" @default.
• W2161577092 type Work @default.
• W2161577092 sameAs 2161577092 @default.
• W2161577092 citedByCount "48" @default.
• W2161577092 countsByYear W21615770922012 @default.
• W2161577092 countsByYear W21615770922013 @default.
• W2161577092 countsByYear W21615770922014 @default.
• W2161577092 countsByYear W21615770922017 @default.
• W2161577092 countsByYear W21615770922019 @default.
• W2161577092 countsByYear W21615770922021 @default.
• W2161577092 countsByYear W21615770922022 @default.
• W2161577092 countsByYear W21615770922023 @default.
• W2161577092 crossrefType "journal-article" @default.
• W2161577092 hasAuthorship W2161577092A5091060989 @default.
• W2161577092 hasConcept C126322002 @default.
• W2161577092 hasConcept C187212893 @default.
• W2161577092 hasConcept C203014093 @default.
• W2161577092 hasConcept C2776723260 @default.
• W2161577092 hasConcept C2779134260 @default.
• W2161577092 hasConcept C2779440204 @default.
• W2161577092 hasConcept C2779969927 @default.
• W2161577092 hasConcept C2779994418 @default.
• W2161577092 hasConcept C2780007613 @default.
• W2161577092 hasConcept C2780674200 @default.
• W2161577092 hasConcept C71924100 @default.
• W2161577092 hasConceptScore W2161577092C126322002 @default.
• W2161577092 hasConceptScore W2161577092C187212893 @default.
• W2161577092 hasConceptScore W2161577092C203014093 @default.
• W2161577092 hasConceptScore W2161577092C2776723260 @default.
• W2161577092 hasConceptScore W2161577092C2779134260 @default.
• W2161577092 hasConceptScore W2161577092C2779440204 @default.
• W2161577092 hasConceptScore W2161577092C2779969927 @default.
• W2161577092 hasConceptScore W2161577092C2779994418 @default.
• W2161577092 hasConceptScore W2161577092C2780007613 @default.
• W2161577092 hasConceptScore W2161577092C2780674200 @default.
• W2161577092 hasConceptScore W2161577092C71924100 @default.
• W2161577092 hasIssue "4" @default.
• W2161577092 hasLocation W21615770921 @default.
• W2161577092 hasLocation W21615770922 @default.
• W2161577092 hasOpenAccess W2161577092 @default.
• W2161577092 hasPrimaryLocation W21615770921 @default.
• W2161577092 hasRelatedWork W2001538418 @default.
• W2161577092 hasRelatedWork W2090958357 @default.
• W2161577092 hasRelatedWork W2126489094 @default.
• W2161577092 hasRelatedWork W2281150386 @default.
• W2161577092 hasRelatedWork W2394614404 @default.
• W2161577092 hasRelatedWork W2419618477 @default.
• W2161577092 hasRelatedWork W2567269117 @default.
• W2161577092 hasRelatedWork W2602069715 @default.
• W2161577092 hasRelatedWork W4319456054 @default.
• W2161577092 hasRelatedWork W43278327 @default.
• W2161577092 hasVolume "30" @default.
• W2161577092 isParatext "false" @default.
• W2161577092 isRetracted "false" @default.
• W2161577092 magId "2161577092" @default.
• W2161577092 workType "article" @default.